Acepodia (ROCO:6976) Cash-to-Debt : 23.54 (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Acepodia Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Acepodia's cash to debt ratio for the quarter that ended in Jun. 2023 was 23.54.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Acepodia could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Acepodia's Cash-to-Debt or its related term are showing as below:

ROCO:6976' s Cash-to-Debt Range Over the Past 10 Years
Min: 22.99 Med: 51.18 Max: 71.11
Current: 22.99

During the past 4 years, Acepodia's highest Cash to Debt Ratio was 71.11. The lowest was 22.99. And the median was 51.18.

ROCO:6976's Cash-to-Debt is ranked better than
65.08% of 1492 companies
in the Biotechnology industry
Industry Median: 6.85 vs ROCO:6976: 22.99

Acepodia Cash-to-Debt Historical Data

The historical data trend for Acepodia's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Acepodia Cash-to-Debt Chart

Acepodia Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

32.45

69.91

71.11

22.99

Acepodia Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial			69.91	N/A	71.11	23.54	22.99

Competitive Comparison of Acepodia's Cash-to-Debt

For the Biotechnology subindustry, Acepodia's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acepodia's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acepodia's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Acepodia's Cash-to-Debt falls into.

Acepodia Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Acepodia's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6293.987	/	(40.361	+	233.45)
	=	22.99

Acepodia's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6634.89	/	(27.83	+	254.079)
	=	23.54

Acepodia (ROCO:6976) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Acepodia Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Acepodia's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Acepodia (ROCO:6976) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acepodia Inc (ROCO:6976) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

17th floor-12, Number 99, Section 1, Xintai 5th Road, Xizhi District, New Taipei, TWN, 22175

Website

https://www.acepodia.com

Acepodia Inc is a clinical stage biotechnology company engaged to develop innovative highly effective first-in-class cell therapies by using Antibody-Cell Conjugation platform technology for cancer that are broadly accessible for patients.

Acepodia (ROCO:6976) Headlines

No Headlines